TABLE 6.
Individual case safety reports of pregnancy loss with intraocular aflibercept.
| No | Age | Drug | Indication | Adverse event | Report year and quarter |
|---|---|---|---|---|---|
| 1 | 47 | Aflibercept (PS), Folic acid (C) | Retinal vein occlusion | Abortion missed | 2014 Q3 |
| 2 | NA | Aflibercept (PS/SS) | Diabetic retinal oedema | Abortion spontaneous. Product use issue | 2016 Q3 |
| 3 | NA | Aflibercept (PS/SS) | Diabetic retinal oedema | Abortion spontaneous, Diabetes mellitus inadequate control | 2017 Q1 |
| 4 | NA | Aflibercept (PS) | Diabetic retinopathy | Stillbirth, Abnormal weight gain, Abnormal loss of weight, Malaise, Renal disorder, Respiratory disorder, Cardiac failure | 2017 Q3 |
Abbreviations: C, Concomitant; NA, not available; PS, primacy suspect drug; SS, secondary suspect drug. Pregnancy-related exposure preferred terms are omitted.